COVID-19 therapeutics I: Drug combination for the therapeutic induction of T cells against COVID-19 (IndTCOVID-19) - clinical trial and immunomonitoring
- Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
- Total publications:1 publications
Grant number: 16LW0005
Grant search
Key facts
Disease
COVID-19Start & end year
20212023Known Financial Commitments (USD)
$1,238,847.36Funder
Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)Principal Investigator
N/A
Research Location
GermanyLead Research Institution
Eberhard Karls Universität TübingenResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Clinical trial (unspecified trial phase)
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Publicationslinked via Europe PMC
Last Updated:2 days ago
View all publications at Europe PMC